TIZIANA LIFE SCIENCES LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8411 USD | +6.45% |
|
+31.42% | +50.20% |
| Apr. 23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
| Apr. 23 | Tiziana Life Sciences Says US FDA Allows Enrollment of 20 More Patients in Foralumab MS Expanded Access Program | MT |
Financials (USD)
| Sales 2021 | - | Sales 2022 | - | Capitalization | 60.66M |
|---|---|---|---|---|---|
| Net income 2021 | -23M | Net income 2022 | -15M | EV / Sales 2021 | - |
| Net cash position 2021 | 42.19M | Net cash position 2022 | 17.76M | EV / Sales 2022 | - |
| P/E ratio 2021 |
-4.01
x | P/E ratio 2022 |
-3.95
x | Employees | 9 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 32.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Tiziana Life Sciences Ltd
More press releases
| 1 day | +6.45% | ||
| 1 week | +31.42% | ||
| Current month | +85.26% | ||
| 1 month | +85.67% | ||
| 3 months | +48.84% | ||
| 6 months | +31.63% | ||
| Current year | +50.20% |
1 week
0.67
0.89
1 month
0.410.89
Current year
0.410.89
1 year
0.411.27
3 years
0.411.70
5 years
0.411.70
10 years
0.411.70
| Managers | Title | Age | Since |
|---|---|---|---|
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 98-02-10 |
Keeren Shah
DFI | Director of Finance/CFO | 47 | - |
Vaseem Palejwala
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 20-06-30 |
Willy Simon
BRD | Director/Board Member | 72 | 15-10-31 |
Gabriele Cerrone
CEO | Chief Executive Officer | 52 | 98-02-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 0.8411 | +6.45% | 881,804 |
| 24-04-24 | 0.7901 | +1.95% | 335,885 |
| 24-04-23 | 0.775 | +2.84% | 2,513,051 |
| 24-04-22 | 0.7536 | +13.15% | 550,057 |
| 24-04-19 | 0.666 | +4.06% | 603,367 |
Delayed Quote Nasdaq, April 25, 2024 at 04:30 pm EDT
More quotes
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company. The Company develops transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Crohn's Disease and KRAS+ NSCLC. Its pipeline candidates include Foralumab (TZLS-401), Anti IL-6R mAb (TZLS-501) and Milciclib (TZLS-201). Foralumab (TZLS-401) is a fully human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohnâs and neurodegenerative diseases. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine. Milciclib is a potent, small molecule inhibitor of multiple cyclin-dependent kinases (CDKs), tropomycinreceptor kinases and Src family kinases controlling cell growth and malignant progression of cancer.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +50.20% | 79.25M | |
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
- Stock Market
- Equities
- TLSA Stock
